Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 4/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464715 | 1.00 | RNASE1 (0.43) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL17052648 | 1.00 | RNASE1 (0.43) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL17056236 | 1.00 | RNASE1 (0.43) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL23102039 | 0.92 | POLG (0.38) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL6517103 | 0.92 | RNASE1 (0.45) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL10331938 | 0.92 | RNASE1 (0.45) | RNASE1DNMT1ADRB1TK1DNMT3B | |
| SCHEMBL16587689 | 0.90 | TK1 (0.36) | RNASE1DNMT1ADRB1TK1POLB | |
| SCHEMBL15280815 | 0.90 | TK1 (0.38) | RNASE1DNMT1ADRB1TK1 | |
| SCHEMBL24517423 | 0.87 | RNASE1 (0.46) | RNASE1DNMT1ADRB1TK1ALB | |
| SCHEMBL14773848 | 0.86 | RNASE1 (0.46) | RNASE1DNMT1ADRB1TK1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| EP-4594491-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | Contera Pharma A/S (DK) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024068997-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2024-04-04 | — | — | WO | disclosed |